Clinical Trials Sponsored by Biogen

Total 2079 results

Biogen

Completed

Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy (OPUS)

Epilepsy, Focal Seizures, Partial Seizures

United States
Biogen

Terminated

Efficacy and Safety Study of BIIB074 in Participants With Small Fiber Neuropathy

Diabetes Mellitus | Small Fiber Neuropathy

Bulgaria, Poland, Spain, United Kingdom, Canada, France, Czechia, Germany, Hungary, Greece, Denmark, Italy, Netherlands, Switzerland
Biogen

No longer available

Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)

Infantile-onset Spinal Muscular Atrophy

New Zealand, Colombia, Turkey
Biogen

Completed

Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants

Healthy Volunteers

United States
Biogen

Completed

Quantitative Magnetic Resonance Imaging (MRI) Sub-Study of MS PATHS

Multiple Sclerosis

United States, Germany
Biogen

Completed

An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) (SMNRx)

Spinal Muscular Atrophy

United States
Biogen

Completed

A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA)

Spinal Muscular Atrophy

United States, Canada
Biogen

Terminated

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (ENDEAR)

Spinal Muscular Atrophy

Korea, Republic of, United States, Spain, Canada, Germany, Australia, Japan, Sweden, Belgium, France, Italy, Turkey, United Kingdom
Biogen

Terminated

A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA). (EMBRACE)

Spinal Muscular Atrophy

United States, Germany
Biogen

Terminated

Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PASSPORT)

Supranuclear Palsy, Progressive

United States, France, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, Austria, Canada, Germany, Japan, Australia, Greece
Biogen

Completed

Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease (PROPEL)

Alzheimer's Disease

Japan
Biogen

Completed

Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera (MITIGATE)

Multiple Sclerosis

United States
Biogen

Completed

A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes (PROTEC)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

France, Italy, Spain, Czechia, Hungary, Austria, Belgium, Canada, Portugal, Slovakia, Slovenia
Biogen

Completed

First-in-Human Study of PF-04958242 in Healthy Volunteers

Healthy Volunteer

Singapore
Biogen

Completed

Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis, Relapsing-Remitting

Poland, Belgium, Turkey, Bulgaria, United States, Czechia, Germany, Kuwait, Latvia, Lebanon
Biogen

Completed

Long-Term Assessment of Remyelinating Therapy (RENEWED)

Acute Optic Neuritis

Sweden, Spain, United Kingdom, Germany, Canada, Denmark, Hungary, Belgium, Czechia, Australia, Italy
Biogen

Completed

An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice (LIBERATE)

Multiple Sclerosis

France, Spain, Germany, Netherlands, Argentina, Czechia, Israel, Portugal, United Arab Emirates, Canada, Norway, Lebanon, Ireland
Biogen

Completed

Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke (ACTION2)

Acute Ischemic Stroke

Spain, United States, Germany, United Kingdom
Biogen

Completed

Clinical Disease Activity With Long Term Natalizumab Treatment

Relapsing-Remitting Multiple Sclerosis

Czechia, Belgium
Biogen

Completed

An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

Korea, Republic of, Taiwan, Czechia, Japan, Poland
Biogen

Completed

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects

Tauopathies

United States
Biogen

Completed

Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS (FOCUS)

Multiple Sclerosis, Relapsing-Remitting

Poland, Turkey, United States, Latvia, Lebanon, Germany, Belgium, Bulgaria, Czechia, Kuwait
Biogen

Completed

Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.

Relapsing Forms of Multiple Sclerosis

United States
Biogen

Completed

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex (SYNERGY)

Multiple Sclerosis

United States, Spain, Hungary, Serbia, Canada, France, Poland, Russian Federation, Netherlands, Czech Republic, Italy, United Kingdom
Biogen

Completed

Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012 (StarTec)

Multiple Sclerosis, Relapsing-Remitting

Italy
Biogen

Completed

Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany (TOLERATE)

Relapsing-Remitting Multiple Sclerosis

Germany
Biogen

Completed

A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants

Systemic Lupos Erythematosus, SLE

United States
Biogen

Completed

PK and Safety Study of BIIB074 in Healthy Japanese and Caucasian Participants

Healthy | Trigeminal Neuralgia

United Kingdom
Biogen

Completed

New Formulation and Food Effect Study of BIIB074

Trigeminal Neuralgia (TN) | Other Neuropathic Pain

United States
Biogen

Completed

The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis

United States
Biogen

Completed

Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen (SFERA)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Clinical Isolated Syndrome (CIS)

Czech Republic, Switzerland
Biogen

Completed

Long-Term Safety and Efficacy Study of Peginterferon Beta-1a (ATTAIN)

Relapsing Multiple Sclerosis

United States, Croatia, Russian Federation, India, Spain, New Zealand, Canada, Belgium, Netherlands, Bulgaria, Serbia, Greece, Ukraine, Mexico, Georgia, Colombia, Germany, Poland, United Kingdom, Czech Republic, France, Chile, Romania, Eston... and more
Biogen

Completed

BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects

Healthy

Netherlands, United States
Biogen

Completed

Safety Study of BIIB033 in Subjects With Multiple Sclerosis

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

United States
Biogen

Completed

Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States
Biogen

Completed

Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis (ASSURE)

Relapsing-Remitting Multiple Sclerosis

United Kingdom, Ireland
Biogen

Completed

JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab (STRATIFY-2)

Relapsing Multiple Sclerosis

United States, Puerto Rico
Biogen

Completed

PK and PD Study of Natalizumab in Pediatric Subjects With RRMS

Relapsing-Remitting Multiple Sclerosis

Italy
Biogen

Completed

Absorption, Metabolism, and Excretion Study of BIIB074

Neuropathic Pain

United States
Biogen

Withdrawn

Brimonidine Tartrate for the Treatment of Injection Related Erythema (BRITE)

Relapsing-Remitting Multiple Sclerosis (RRMS)
Biogen

Terminated

104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants (RESPOND-EXT)

Rheumatoid Arthritis

Argentina, Brazil, Hungary, Mexico, Poland, Romania, Russian Federation, United Kingdom
Biogen

Terminated

BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Biogen

Withdrawn

Systemic Sclerosis Clinical and Biomarker Study

Healthy | Systemic Sclerosis
Biogen

Completed

Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study (AVAIL)

Multiple Sclerosis

Belgium
Biogen

Completed

Observational Study to Establish Patient-Matched Population Norms for the Multiple Sclerosis Cognition Assessment Battery

Healthy

United States, Italy, France
Biogen

Terminated

Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

France, United States, Belgium, Australia, Austria, Poland, Canada, United Kingdom
Biogen

Completed

Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
Biogen

Completed

An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)

GIST

United States
Biogen

Completed

BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy (SPRINT)

Sciatica | Radiculopathy | Painful Lumbar Radiculopathy

United States
Biogen

Completed

Single-Dose Study of a New Formulation of BIIB061

Multiple Sclerosis

United States

3

Subscribe